Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - brolucizumab - rastvor za injekciju u napunjenom špricu - 120 mg/1 ml - jedna napunjena šprica sadrži 19,8 mg brolucizumaba u 0,165 ml rastvora

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"novartis pharma services ag" dio stranog druŠtva podgorica - ranibizumab - rastvor za injekciju - 10mg/ml

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"novartis pharma services ag" dio stranog druŠtva podgorica - brolucizumab - rastvor za injekciju u napunjenom injekcionom špricu - 120mg/ml

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"novartis pharma services ag" dio stranog druŠtva podgorica - brolucizumab - rastvor za injekciju - 120mg/ml

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"hoffmann-la roche ltd" d.s.d. podgorica - faricimab - rastvor za injekciju - 120mg/ml

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - aflibercept - rastvor za injekciju - 40mg/ml